SCHEMBL16183435

SCHEMBL16183435

CNc1nc(-c2cnccn2)nc2cc(-c3cc(OC)cc(OC)c3)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 2/20 0.46
▸ LATS1 O95835 2/20 0.43
▸ LATS2 Q9NRM7 1/20 0.43
▸ CYP1A2 P05177 5/20 0.41
▸ CYP3A4 P08684 5/20 0.41
▸ CYP2D6 P10635 5/20 0.41
▸ CYP2C19 P33261 5/20 0.41
▸ CYP2C9 P11712 3/20 0.41
▸ CLK4 Q9HAZ1 3/20 0.41
▸ LMNA P02545 3/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ USP2 O75604 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ ABCB1 P08183 2/20 0.39
▸ ABCG2 Q9UNQ0 2/20 0.39
▸ LIMK1 P53667 6/20 0.38
▸ LIMK2 P53671 6/20 0.38
▸ TESK1 Q15569 3/20 0.38
▸ TESK2 Q96S53 3/20 0.38
▸ MEN1 O00255 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16183429 0.92 SYK (0.52) SYKLATS1LATS2CYP1A2CYP3A4
SCHEMBL16183428 0.92 CYP1A2 (0.52) SYKCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL16183434 0.87 ABCG2 (0.45) SYKLATS1LATS2CYP1A2CYP3A4
SCHEMBL16183431 0.85 SYK (0.44) SYKLATS1LATS2CYP1A2CYP3A4
SCHEMBL16183432 0.85 DHFR (0.48) SYKLATS1LATS2CYP1A2CYP3A4
SCHEMBL16183733 0.84 LATS1 (0.44) SYKLATS1LATS2CYP1A2CYP3A4
SCHEMBL16184187 0.84 LATS1 (0.44) SYKLATS1LATS2CYP1A2CYP3A4
SCHEMBL16184179 0.84 LATS1 (0.46) SYKLATS1LATS2CYP1A2CYP3A4
SCHEMBL16184164 0.84 CYP1A2 (0.55) SYKLATS1LATS2CYP1A2CYP3A4
SCHEMBL16183728 0.84 LATS1 (0.46) SYKLATS1LATS2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB SYK 519/4885LATS1 2182/4885LATS2 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback